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ABSTRACT
Aim: To determine the carrier frequency of ABCA4
mutations in order to achieve an insight into the
prevalence of autosomal recessive Stargardt disease
(arSTGD) in the Spanish population.
Methods: arSTGD patients (n=133) were analysed
using ABCR400 microarray and sequencing. Control
subjects were analysed by two different strategies: 200
individuals were screened for the p.Arg1129Leu mutation
by denaturing-HPLC and sequencing; 78 individuals were
tested for variants with the microarray and sequencing.
Results: For the first strategy in control subjects, the
p.Arg1129Leu variant was found in two heterozygous
individuals, which would mean a carrier frequency for any
variant of ,6.0% and a calculated arSTGD prevalence of
1:1000. For the second strategy, carrier frequency was
6.4% and therefore an estimated prevalence of the
disease of 1:870.
Conclusion: Calculated prevalence of arSTGD based on
the ABCA4 carrier frequency could be considerably higher
than previous estimation. This discrepancy between
observed (genotypic) and estimated (phenotypic) pre-
valence could be due to the existence of non-pathological
or low penetrance alleles, which may result in late-onset
arSTGD or may be implicated in age-related macular
degeneration. This situation should be regarded with
especial care when genetic counselling is given and
further follow-up of these patients should be recom-
mended.
Stargardt disease (STGD1, MIM #248200) is the
most common hereditary macular dystrophy
affecting children, with a prevalence of approxi-
mately 1:10 000 and a carrier frequency of ,2%.
1 It
is characterised by central visual loss, atrophy of
the retinal pigment epithelium (RPE) that resem-
bles a ‘‘beaten-bronze’’ appearance, and the dis-
tribution of orange-yellow flecks around the
macula and midperiphery of the retina.
2 STGD is
predominantly inherited as an autosomal recessive
trait, although an autosomal dominant form has
been also described.
3 Bi-allelic mutations in ABCA4
are found in most patients with autosomal
recessive STGD (arSTGD)
4 and in some patients
with autosomal recessive retinitis pigmentosa
(arRP),
5 autosomal recessive cone-rod dystrophy
(arCRD)
6 and age-related macular degeneration
(AMD).
7
Up to now, approximately 500 disease-causing
mutations have been identified in ABCA4. The
mutation spectrum ranges from single base
substitutions to deletions of several exons or
uniparental disomies,
89although the majority of
reported changes are missense mutations (http://
www.hgdm.cf.ac.uk/ac/index.php). In addition,
heterozygote carrier frequency is particularly high
in the general population.
10 Previous mutational
analyses performed in Spanish arSTGD patients led
to the identification of a prevalent disease-asso-
ciated allele, the p.Arg1129Leu variant.
11
Because of the relatively large size of this gene,
containing 50 exons, the molecular scanning of
ABCA4 is particularly labour-intensive. The
ABCR400 chip (Asper Biotech, Tartu, Estonia) has
become a reliable and rapid mutation detection tool
and, as previously described, was .98% effective in
screening for disease-associated alleles.
10 However,
because of the high frequency of rare mutations
reported in this gene, additional mutational scan-
ning should be carried out by denaturing-HPLC
(dHPLC).
12 This results a more effective screening
tool for ABCA4 variants than previous methods such
as double gradient-denaturing gradient gel electro-
phoresis (DG-DGGE).
13 This technique is especially
applicable for those ABCA4 patients for whom the
chip found one or no mutations. Obtained results
from both techniques should be confirmed by direct
sequencing, which is still considered the ‘‘gold
standard’’ method for mutation detection, and
enables the identification from 66–80% of the
ABCA4 disease-associated alleles.
14 15
The aim of this study was to determine the
frequency of ABCA4 mutations in control indivi-
duals. According to these mutational findings and
allelic frequencies calculations such as the Hardy–
Weinberg equilibrium, we aimed to achieve an
insight into the prevalence of arSTGD in the
Spanish population. To overcome this challenge we
designed a case–control study that combined
several high-throughput and cost-effective screen-
ing tools such as ABCR400 genotyping microarray,
dHPLC and direct sequencing.
PATIENTS AND METHODS
A case–control study was designed. Methods are
described as follows.
Recruitment of patients
Thorough clinical ophthalmic and electrophysiolo-
gical examinations were performed in arSTGD
patients, including comprehensive ophthalmologi-
cal and family history, funduscopic examination
after pupillary dilation, static perimetry, best
corrected visual acuity, colour vision testing and
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included full-field electroretinogram (ERG) according to stan-
dards of the International Society for Clinical Electrophysiology
of Vision (ISCEV).
16 17
Ascertainment of controls
Healthy control individuals were recruited from anonymous
blood donors from the blood service of the Fundacion Jimenez
Diaz Hospital, Madrid, Spain. Subjects had previously given
informed consent where their nationality, age and sex were
stated. Recent immigrants were excluded from the study, thus
ensuring a homogeneous genetic background.
Molecular approach in arSTGD patients
Data from 133 arSTGD patients were analysed using the
ABCR400 genotyping microarray;
10 results were confirmed by
direct sequencing.
Molecular approach in control population
Control individuals were analysed following to two different
strategies in order to compare both results and to further
determine whether there were significant differences. For both
strategies, allelic frequencies were estimated by the Hardy–
Weinberg equilibrium (p
2+2pq+q
2=1) and 95% CI was calcu-
lated for obtained carrier frequencies; statistical data were
analysed by the chi-square test (fig 1).
First strategy
As previously described,
11 the frequency of the p.Arg1129Leu
allele is notably high in Spanish patients. Therefore, 200
subjects (400 chromosomes) from a control population were
tested for this variant by cost-effective dHPLC technique. Those
samples presenting an abnormal chromatographic pattern were
sequenced. The carrier frequency for any ABCA4 variant was
then extrapolated.
Second strategy
In a different subset of 78 subjects (156 chromosomes), the
ABCA4 carrier frequency was determined by screening samples
on the ABCR400 microarray; results were confirmed by direct
sequencing.
Molecular methods
DNA extraction
Peripheral blood samples were taken and genomic DNA was
extracted using an automated DNA extractor (BioRobot EZ1,
QIAGEN, Hilden, Germany).
Genotyping microarray
arSTGD patients were analysed for variants on the ABCR400
microarray (www.asperbio.com), as described elsewhere.
10 The
50 exons of the ABCA4 gene, including the intron–exon
junctions, were amplified by PCR primers previously
described,
18 in order to confirm the results obtained from the
microarray.
Direct sequencing
Sequencing reactions were performed using the four dye
terminator cycle sequencing ready reaction kit (dRhodamine
DNA Sequencing Kit; Applied Biosystems, Foster City,
California, USA). Sequence products were purified through fine
columns (Sephadex G-501, Princetown Separations, Adelphia,
New Jersey, USA) and resolved in an ABI Prism 3100 (Applied
Biosystems).
dHPLC
dHPLC sample screening was performed on a DNA fragment
analysis system (WAVE, Transgenomic, Omaha, Nebraska,
USA), as described elsewhere.
12
RESULTS
Cases
Seventy-six of the 133 Spanish arSTGD patients have been
previously reported on by our group.
11 Nevertheless, they have
been included in the present study in order to achieve a more
accurate mutation detection rate for the genotyping microarray,
as it is currently updated with novel disease-associated alleles.
Of the 266 arSTGD chromosomes studied, mutations were
identified in 161, resulting in a detection rate for the genotyping
microarray of 60.5%: two mutant alleles were found in 64/133
patients (48.1%), whereas in 33/133 cases (24.8%) only one
allele could be identified. A total of 56 different sequence
variants related to the disease were identified, including
missense (42), nonsense (four) frameshift (five) and splicing
(five) mutations. Furthermore, combinations of variants acting
in cis (complex alleles; six double alleles, one triple allele) were
also found. Of this spectrum of substitutions, the p.Arg1129Leu
(c.3386G.T) allele accounted for 26% of the disease-associated
alleles (fig 2). Considering the percentage represented by this
variant in patients (26%) and the obtained mutation detection
rate (60.5%), this change would represent the 15.7% of all the
potential arSTGD associated alleles.
Controls
Analysis of 400 chromosomes
Because of its high frequency in the group of patients with
arSTGD, we determined the presence of the p.Arg1129Leu
mutation in 200 control individuals from Spain. By use of
dHPLC, this allele was found in two heterozygous individuals
(allelic frequency=2/400=0.005). Next, we extrapolated the
carrier frequency for any ABCA4 variant (absolute mutant
frequency; q value), considering the current frequency of the
p.Arg1129Leu allele in arSTGD patients (15.7%), resulting in
q=0.032. Given these allelic frequencies, we applied the Hardy–
Weinberg equilibrium, obtaining an estimated heterozygous
carrier frequency (2pq value) of 5.99% with 95% CI 1.35 to
10.63. Therefore, the arSTGD prevalence would be 1:1000.
Analysis of 156 chromosomes
Following the screening on the ABCR400 chip, ten hetero-
zygous individuals were identified. Interestingly, this fraction
includes only missense disease-associated alleles. No additional
variants were found in the remaining controls, but common
polymorphisms (table 1). Therefore, carrier frequency was 6.4%
(ten mutant alleles out of 156) with 95% CI 1.62 to 11.18. By
applying the Hardy–Weinberg equilibrium, an estimated pre-
valence of the disease of 1:870 was obtained.
Statistical analysis
Differences between genotyping strategies in controls
Calculated prevalence values resulting from both genotyping
strategies (p.Arg1129Leu screening, prevalence: 1:1000 vs.
microarray screening, prevalence: 1:870) were compared using
the chi-square test, but this analysis did not reveal a significant
difference (a=0.05).
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prevalence
The chi-square test (a=0.05) was significant when comparing
previous prevalence (1:10 000) with the present results.
Differences of the frequency of the p.Arg1129Leu allele between
patients and controls
In addition, the frequency of p.Arg1129Leu variant was tested
between in arSTGD patients and controls. The chi-square test
Figure 1 Algorithm representing the case–control study: two different molecular approaches were performed; results were compared by statistical
analysis. ar, autosomal recessive; dHPLC, denaturing-HPLC; STGD, Stargardt disease.
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confirming more association in the patient group.
DISCUSSION
Rare diseases are those considered to be less frequent than
1:3000. This classification comprises the heterogeneous group of
inherited retinal dystrophies, which includes both central
(macular) or peripheral retinopathies. Up to now, arSTGD
was thought to be the most common juvenile macular
dystrophy, but still considered within the group of rare diseases.
Current prevalence of the disease has been established in one
affected individual per 10 000 live births,
1 thus indicating a
carrier frequency of approximately 2%.
To evaluate the arSTGD prevalence further, we proposed two
different strategies for determining the carrier frequency of
ABCA4 disease-associated alleles in a Spanish control popula-
tion. In one strategy, the arSTGD prevalence was calculated
over the frequency of the most common allele (p.Arg1129Leu)
in 400 ethnically matched control chromosomes. In the other,
78 control subjects were directly screened for variants and the
subsequent prevalence of the disease was assessed. These
molecular approaches were based on the mutation detection
rate of the high-throughput ABCR400 microarray, which we
previously tested
11 and confirmed in Spanish arSTGD patients
(present study). Jaakson et al
10 reported that the array is
theoretically able to detect about 56% of the disease-associated
alleles in populations of European origin. In our set of samples,
including 76 previously analysed arSTGD patients, 161 poten-
tial disease-associated alleles were identified, yielding a detec-
tion rate of 60.5% by the ABCR400 chip. Considering these
results, mutation detection might only be increased by
additional molecular scanning performed either by dHPLC or
direct sequencing. Both techniques are the most suitable tools
for the identification of novel ABCA4 variants not yet contained
in the chip.
As Valverde et al previously reported,
11 the patterns of the
disease-associated alleles were significantly different from those
described at other European populations. In our Spanish
arSTGD patients, the most frequent mutation was the missense
p.Arg1129Leu variant, accounting for 26% of the disease-
associated alleles (fig 2), that is approximately one out of about
four (3.84) of the arSTGD alleles. Given this high frequency for
a specific allele, the control population was tested for this
variant. We were able to identify that the presence of this
sequence change was significantly higher in patients than in
controls (chi-square test; a=0.05). The p.Arg1129Leu allele was
found in two heterozygous individuals out of 278 (two
heterozygous individuals out of 200 screened by dHPLC; zero
individuals out of 78 screened by the ABCR400 chip), yielding
an allelic frequency of 0.36%; this supports the notion of a
pathogenic change as this variant is less frequent than 1%.
Moreover, the biochemical characterisation of a recombinant
ABCR protein with the p.Arg1129Leu mutation revealed a
substantial reduction in both expression and ATP-binding
activity.
19 In our 133 STGD families, seven were homozygous
for the p.Arg1129Leu allele (five of them have been described
previously).
11 In addition, haplotype analysis with markers
flanking the ABCA4 gene (TEL-D1S435-D1S2804-ABCA4-
D1S236-CEN) showed co-segregation of the disease within
these families. Moreover, mutation segregation was observed
among unaffected members of these cohorts (results available
on request).
The frequency of this mutation in the control population
would mean an estimated carrier frequency for any ABCA4
variant of 5.99% (95% CI 1.35 to 10.63). In consequence, the
estimated arSTGD prevalence would be 1:1000, which is ten
times higher than current 1:10 000 value. Furthermore, this
result was confirmed by a second control population screening
performed by the ABCR400 microarray. This analysis resulted
in a carrier frequency of 6.4% (95% CI 1.62 to 11.18) and
Figure 2 The spectrum of ABCA4 disease-associated alleles identified in Spanish Stargardt disease (STGD) patients and relative frequencies. Of these,
the prevalent p.Arg1129Leu variant represented the 26% of the mutant alleles.
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is more that 11.5 times greater than 1:10 000. When comparing
both strategies, statistical analyses did not show significant
differences. Nevertheless, the tests were significant when
comparing our results with previous prevalence of arSTGD.
Different techniques, with distinct mutation detection rates,
have been used to assess the heterozygote carrier frequency.
Nevertheless, the comparison between them seems reasonable
since all results have been confirmed by direct sequencing,
which is still considered the gold standard method. However,
these estimations of prevalence should be regarded with certain
caution, as they depend highly on one assumption (the
p.Arg1129Leu frequency in arSTGD patients should be propor-
tional to the p.Arg1129Leu frequency in controls) that is never
entirely fulfilled.
Whereas the precise prevalence of arSTGD is still not known,
we have observed a discrepancy between the observed
(genotypic) values (1:1000; 1:870) and the estimated (pheno-
typic) (1:10 000) prevalence of the disease. This difference could
be due to the existence of combinations of different alleles that
are not pathological or, at least, do not result in an early-onset
phenotype (low penetrance alleles). Therefore, this approach
might be used to assess the amount of pathogenicity
attributable to each ABCA4 allele. For example, if we get a high
arSTGD prevalence caused by a concrete allele, this would mean
that this variant is a polymorphism or a ‘‘mild allele’’ rather
than a pathogenic change. Indeed, it has been suggested that the
homozygous mild c.2588G.C allele does not cause arSTGD.
20 If
the prevalence of the disease was calculated over the frequency
of this common variant it would result in a prevalence of 1:58 in
European populations, which reinforces the hypothesis of being
a mild allele and only being pathogenic when associated with
another severe to moderate disease-causing allele.
By contrast, if the relative allelic frequency for one change is
low, that change could be classified as a disease-causing allele.
Moreover, this last hypothesis would be reinforced by the
scarcity of a concrete allele together with having a frameshift or
splicing effect, and possibly associated with a more severe
phenotype, such as cone-rod dystrophy or retinitis pigmentosa.
In fact, the c.2888delG variant has been described as the most
frequent allele in Spanish cone-rod dystrophy patients, whereas
it has not been associated with the arSTGD phenotype.
21
Regarding to the genetic diagnosis and counselling of arSTGD
patients, a few points should be considered. (1) High-
throughput techniques are able to detect a wider spectrum of
mutations in ABCA4 than before, achieving higher mutation
detection rates. (2) Accurate clinical diagnosis and thorough
ophthalmic examination of inherited retinopathies are now
possible, thus providing a more comprehensive management of
the disease and offering the possibility of molecular analysis. (3)
Previous studies have found that 5–12% of the general
population carry disease-associated ABCA4 alleles.
71 01 82 0In this
study, we have identified significant percentages of carriers,
with values of about 20% (table 2).
Moreover, if we consider that this value has been obtained
through screening on the ABCR400 chip (mutation detection
rate=60.5%) and the high frequency of rare mutations reported
in this gene, this percentage could be even higher. These
Table 1 ABCA4 sequence variants identified in Spanish control population
Mutant alleles
Nucleotide
change Amino acid change
Number of
cases
Number of
alleles
Frequency
(%)
Homozygous
individuals
Mutations* c.661G.A p.Gly221Arg 1 1 0.64 None
c.1140T.A p.Asn380Lys 1 1 0.64 None
c.2588G.C p.Gly863Ala 1 1 0.64 None
c.3113C.T p.Ala1038Val 1 1 0.64 None
c.3899G.A p.Arg1300Gln 1 1 0.64 None
c.5882G.A p.Gly1961Glu 1 1 0.64 None
c.5908C.T p.Leu1970Phe 1 1 0.64 None
c.6148G.C p.Val2050Leu 1 1 0.64 None
c.6529G.A p.Asp2177Asn 2 2 1.28 None
Total 10
Polymorphisms{ c.466A.G p.Ile156Val 5 5 3.2 None
c.635G.A p.Arg212His 5 6 3.84 1
c.1268A.G p.His423Arg 43 48 30.7 5
c.1269C.T p.His423His 2 2 1.28 None
IVS10+5delG 34 36 23 2
c.2828G.A p.Arg943Gln 1 1 0.64 None
c.4203C.A p.Pro1401Pro 3 3 1.9 None
IVS33+48C.T5 9 7 5 4 8 1 6
c.5603A.T p.Asn1868Ile 4 4 2.5 None
c.5682G.C p.Leu1894Leu 29 35 22.4 6
c.5814A.G p.Leu1938Leu 27 33 21.1 6
c.5843 C.T p.Pro1948Leu 9 10 6.4 1
c.5844A.G p.Pro1948Pro 27 32 20.5 5
c.6069C.T p.Ile2023Ile 11 12 7.7 1
c.6249C.T p.Ile2083Ile 12 14 8.9 2
c.6285T.C p.Asp2095Asp 24 26 16.6 2
c.6764G.T p.Ser2255Ile 12 13 8.3 1
*A total of 15 mutant alleles were detected.
{Polymorphisms identified in control individuals: eight out of 16 were synonymous codon variants. In addition, the decision criteria
for being non-pathogenic changes were supported by the existence of unaffected individuals harbouring homozygous variants.
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and, in consequence, a need for revision of the present value.
However, this estimated prevalence does not correlate with the
expected prevalence of the disease and questions the pathogenic
significance of some mutations. The combination of these
alleles with low penetrance should be regarded especially
carefully when genetic counselling is given and further follow-
up of these patients should be recommended in order to
establish an accurate genotype–phenotype correlation. (4) The
findingofahighercarrierfrequencyshouldbecarefullyconsidered
when dealing with retinal dystrophies resembling any of the
phenotypes attributable to ABCA4: arSTGD, arCRD or arRP. In
addition, as being carrier of an ABCA4 disease-associated allele
shouldgiveanincreasedriskfor AMD,
7 healthy parents or siblings
of arSTGD patients should receive an appropriate eye care when
diagnosed, especially before becoming elderly.
For those populations where the spectrum of ABCA4
mutations is known and considering that allelic frequencies
differ from one country to another, the use of a cost-effective
strategy similar to the one described in this study, based on
carrier frequency screenings, might be recommended to assess
the estimated (genotypic) prevalence of arSTGD. Moreover, this
type of approach can also be applied to other non-retinal
diseases where the mutational spectrum is well-known or the
evidence of a prevalent disease-associated allele has been
demonstrated.
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